Market Newsdesk

CORNELIUS, N.C., April 29, 2026 (GLOBE NEWSWIRE) — Alpha Modus Holdings, Inc. (“Alpha Modus”) (NASDAQ: AMOD), through its subsidiary Alpha Modus Financial Services, LLC, today announced an Account Load Services Agreement with InComm Payments. The agreement will enable Alpha Cash customers to make cash deposits to their accounts at over 90,000 locations across the country via InComm Payments’ VanillaDirect barcode technology and retail network.

Alpha Cash customers will be able to present their in-app generated digital barcode, along with physical cash, at any participating InComm Payments retail location to add funds instantly. VanillaDirect provides Alpha Cash with a scalable physical cash deposit channel, extending embedded financial services to underserved consumers at retail locations where they already shop, without requiring a bank branch or ATM.

“Alpha Cash is a delivery mechanism for consumer-facing financial intelligence, and InComm Payments gives us the cash-in technology and physical distribution to match that ambition,” said William Alessi, Chief Executive Officer of Alpha Modus Holdings, Inc. “This agreement should extend our reach across thousands of retail locations without deploying a physical kiosk, allowing for a mobile first experience. We are building the spine before the scale.”

“InComm Payments’ VanillaDirect network is the right infrastructure to compound the financial services ecosystem we’ve assembled,” said Chris Chumas, Chief Strategy Officer of Alpha Modus Holdings, Inc. “With this integration, Alpha Cash will provide our cash-based consumers with an onramp to digital infrastructure without a traditional bank account.”

“As financial experiences become increasingly embedded into everyday apps and services, ensuring cash remains part of this digital ecosystem is essential for the consumers that use it and depend on it,” said Mark Smith, Vice President at InComm Payments. “We are excited to bring our world-class network of retailers to Alpha Modus and their customers.”

The InComm Payments agreement advances Alpha Modus’s strategy of building a fully integrated, consumer-facing financial services platform. As previously announced, the Alpha Cash partner stack includes embedded banking, national remittance and bill pay, check cashing and money transfer, prepaid mobile and digital value.

About Alpha Modus Holdings, Inc.

Alpha Modus Holdings, Inc. (“Alpha Modus” or the “Company”) (NASDAQ: AMOD) is a vertical AI company focused on real-time, in-store shopper engagement and attribution. Its patented “closed-loop” retail AI framework, Sense → Decide → Deliver → Attribute, enables brands and retailers to measure the full impact of digital content, physical interactions, and transaction outcomes. Through subsidiaries like Alpha Modus Financial Services, the company is actively deploying technologies that merge artificial intelligence, retail media, and financial access across the physical retail landscape
.
For more information, visit:

www.alphamodus.com

Alpha Modus maintains a comprehensive overview of its patent portfolio on its website:

https://alphamodus.com/what-we-do/patent-portfolio/
.

For more information and to access Alpha Modus’ press room, visit: https://alphamodus.com/press-room/

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Alpha Modus’s actual results may differ from their expectations, estimates, and projections, and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements, but are not the exclusive means of identifying these statements. These forward-looking statements include, without limitation, Alpha Modus’s expectations with respect to future performance.

Alpha Modus Holdings, Inc. (“Alpha Modus”) cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Alpha Modus does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.

Contact Information

Investor Relations
Alpha Modus Holdings, Inc.
Email: [email protected]
Website: www.alphamodus.com

Follow us on LinkedIn | Follow us on X

About InComm Payments

InComm Payments is an innovative global payments technology provider. Leveraging dynamic technology and proven expertise, InComm Payments delivers enhanced end-to-end payment platforms and emerging financial technology solutions through a single integration, helping businesses grow across a wide range of industries including retail, healthcare, tolling & transit, incentives, mobile payments, digital currencies and financial services. By enabling omnichannel connections and alternative payment options to an ever-expanding consumer base in an increasingly digital ecosystem, InComm Payments creates seamless and valuable commerce experiences across the globe. With three decades of experience, over 525,000 points of retail and online distribution, 412 global patents and a presence in more than 40 countries, InComm Payments leads the payments industry from its headquarters in Atlanta, Ga. Learn more at www.InCommPayments.com.

For more information on InComm Payments and its cash solutions, please visit www.incomm.com/payments/cash-solutions.

EVERSANA, a purpose-built, partner-led commercial organization, positions Candel for potential U.S. commercial launch following planned BLA submission in Q4 2026

NEEDHAM, Mass., April 29, 2026 (GLOBE NEWSWIRE) — Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to help patients with cancer, today announced that it entered into a product commercialization agreement (the “Agreement”) with EVERSANA^®, a leading provider of global commercialization services to the life sciences industry, to support the potential U.S. commercial launch of aglatimagene besadenovec (aglatimagene or CAN-2409) for the treatment of intermediate- to high-risk, localized prostate cancer.

Under the terms of the agreement, EVERSANA will provide Candel with a broad suite of integrated commercialization services including data and analytics, medical affairs, market access and field operations. EVERSANA joins IDEA Pharma, a division of SAI MedPartners (IDEA), which has been providing path-to-market strategies and strategic positioning for aglatimagene. Candel has worked in close collaboration with both EVERSANA and IDEA on key pre-commercial workstreams as previously announced during Candel’s virtual Research and Development Day in December 2025.

This collaboration reflects Candel’s deliberate approach to building a world class commercial organization with global reach, designed from the ground up and leveraging a team of highly experienced professionals poised to support the potential commercial launch of aglatimagene for the treatment of intermediate- to high-risk, localized prostate cancer, subject to regulatory approval. This operating model gives Candel access to leading commercial capabilities while maintaining financial flexibility, capital efficiency, and scientific focus that has driven Candel’s progress to date.

“From the beginning, we designed Candel’s commercial strategy around a partner-led model that allows us to stay focused on advancing the science and navigating the regulatory pathway, while having access to world-class commercial capabilities on demand,” said Paul Peter Tak, M.D., Ph.D., FMedSci, President and Chief Executive Officer of Candel. “With the addition of EVERSANA, that model is fully in place, and with the progress we’ve already made across our pre-commercialization workstreams, we have confidence in our readiness for the potential commercial launch of aglatimagene for the treatment of intermediate- to high-risk, localized prostate cancer. We look forward to working with EVERSANA and IDEA Pharma in providing a novel and potentially invaluable therapeutic for localized prostate cancer patients.”

“We are proud to support Candel as it advances what could be a new and potentially transformative treatment option for patients with localized prostate cancer,” said Gregory Skalicky, President of EVERSANA. “Candel’s unique approach to commercialization, building a dedicated and flexible platform with specialized partners, rather than a fixed pharmaceutical infrastructure, is exactly the type of model EVERSANA was designed to support. We have already integrated our resources alongside the Candel team, with key commercial workstreams actively underway, and we look forward to helping ensure that aglatimagene reaches patients efficiently and effectively upon potential approval.”

About EVERSANA^®

EVERSANA^® is a leading independent provider of global services to the life sciences industry. Eversana’s integrated solutions are rooted in the patient experience and span all stages of the product life cycle to deliver long-term, sustainable value for patients, prescribers, channel partners and payers. Eversana serves more than 650 organizations, including innovative start-ups and established pharmaceutical companies, to advance life sciences solutions for a healthier world. To learn more about EVERSANA^®, visit eversana.com or connect through LinkedIn and X.

About aglatimagene besadenovec

Aglatimagene, Candel’s most advanced multimodal biological immunotherapy candidate, is an investigational, off-the-shelf, replication-defective adenovirus designed to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to a patient’s tumor. After intratumoral administration, HSV-tk enzyme activity results in conversion of prodrug (valacyclovir) into deoxyribonucleic acid (DNA)-incorporating nucleotide analogs, leading to immunogenic cell death in cells exhibiting DNA damage and proliferating cells, with subsequent release of a variety of tumor (neo)antigens in the tumor microenvironment. At the same time, the adenoviral serotype 5 capsid proteins promote inflammation through the induction of expression of pro-inflammatory cytokines, chemokines, and adhesion molecules. Together, this regimen is designed to induce an individualized and specific CD8+ T cell-mediated response against the injected tumor and uninjected distant metastases for broad anti-tumor activity, based on in situ immunization against a variety of tumor antigens. Aglatimagene has the potential to treat a broad range of solid tumors. Encouraging monotherapy activity, as well as combination activity with standard of care radiotherapy, surgery, chemotherapy, and immune checkpoint inhibitors have previously been shown in several preclinical and clinical settings. More than 1,000 patients have been dosed with aglatimagene in clinical trials with a favorable tolerability profile to date, supporting the potential for combination with standard of care, when indicated. Aglatimagene is currently not approved by the U.S. Food and Drug Administration (FDA).

About Candel Therapeutics

Candel is a clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. Aglatimagene is the lead product candidate from the adenovirus platform. The Company recently completed successful phase 2a clinical trials of aglatimagene in non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC), and a pivotal, placebo-controlled, phase 3 clinical trial of aglatimagene in localized prostate cancer, conducted under a Special Protocol Assessment agreed with the FDA. The FDA also granted Fast Track Designation and Regenerative Medicine Advanced Therapy Designation to aglatimagene for the treatment of newly diagnosed localized prostate cancer in patients with intermediate-to high-risk disease, Fast Track Designation in NSCLC, and both Fast Track Designation and Orphan Drug Designation to aglatimagene for the treatment of PDAC.

Linoserpaturev (CAN-3110) is the lead product candidate from the HSV platform and is currently in an ongoing phase 1b clinical trial in recurrent high-grade glioma, evaluating the effects of repeat linoserpaturev injections. Initial results were published in Nature and Science Translational Medicine, and linoserpaturev received Fast Track Designation and Orphan Drug Designation from the FDA. Finally, Candel’s enLIGHTEN™ Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors.

For more information about Candel, visit: www.candeltx.com.

Forward-Looking Statements

This press release includes certain disclosures that contain “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding the timing and advancement of current and future development programs; expectations regarding the submission of the BLA for aglatimagene in intermediate- to high-risk localized prostate cancer; expectations regarding the Company’s ability to prepare and implement commercialization plans for aglatimagene in partnership with EVERSANA and IDEA and the potential benefits and duration of such partnerships; expectations regarding early biological readouts as predictor of clinical response; expectations regarding the therapeutic benefit of the Company’s programs, including the ability of aglatimagene to treat a broad range of solid tumors and improve disease-free survival, overall survival, and post-progression survival; and expectations regarding the potential benefits conferred by regulatory designations.  The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to the timing and advancement of development programs; expectations regarding the therapeutic benefit of the Company’s programs; that final data from the Company’s pre-clinical studies and completed clinical trials may differ materially from reported interim data from ongoing studies and trials; the Company’s ability to efficiently discover and develop product candidates; the Company’s ability to obtain and maintain regulatory approval of product candidates; the Company’s ability to maintain its intellectual property; the implementation of the Company’s business model, including strategic plans for the Company’s business and product candidates; the Company’s ability to successfully prepare and implement commercialization plans for aglatimagene with its strategic partners, the impact of the Company’s existing and any future indebtedness on its ability to operate its business; the Company’s ability to access any future tranches under its debt facility and to comply with all of its obligations thereunder and other risks identified in the Company’s filings with the U.S. Securities and Exchange Commission (SEC) including the Company’s most recent Annual Report on Form 10-K filed with the SEC and any subsequent filings with the SEC. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent the Company’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.

Investor Contact:

Theodore Jenkins                                                                                        
VP, Investor Relations and Business Development                                                            
Candel Therapeutics, Inc.                                                      
[email protected]

Media Contact:
Ben Shannon
ICR Healthcare        
[email protected]

EVERSANA Contact:

Matt Braun
Vice President, Corporate Communications
[email protected]

AVENTURA, Fla., April 29, 2026 (GLOBE NEWSWIRE) — Safe Pro Group Inc. (Nasdaq: SPAI) (“Safe Pro” or the “Company”), a developer of artificial intelligence (AI)-enabled defense, security, and situational awareness solutions, today announced that it has entered into a Master Teaming agreement (the “Agreement”) with a U.S. government prime defense contractor (the “Prime”) to pursue and deliver AI-powered air and ground autonomy solutions in support of the U.S. Government.

Under the Agreement, Safe Pro and the Prime will collaborate on the development, integration, and deployment of next-generation battlefield intelligence solutions that combine AI-powered threat detection with autonomous air and ground platforms. The parties intend to leverage Safe Pro’s patented Safe Pro Object Threat Detection (SPOTD) AI platform, NODE-X edge compute systems, and computer vision technologies for use with drones and autonomous ground vehicles to deliver real-time situational awareness and force protection at the tactical edge. The teaming arrangement is expected to support the pursuit of additional program opportunities where Safe Pro’s AI capabilities can be integrated into larger Prime-led autonomous platforms.

The new Agreement expands an existing contract under which the Company rapidly executed on a $1,000,000 U.S. Government subcontract for AI edge processing systems and has continued to receive follow-on support tasking tied to the deployment of those systems.

“Through this new teaming agreement, we have an opportunity to significantly expand our relationship with a leading U.S. defense prime and build upon our shared commitment to harness AI and autonomous technologies to deliver actionable battlefield intelligence to the U.S. Army and allied forces,” said Dan Erdberg, Chairman and CEO of Safe Pro Group Inc. “The modern battlefield is rapidly connecting drones and unmanned ground and sea vehicles, creating a pressing need to collect and analyze real-world data at the edge. By pairing our SPOTD AI platform and NODE-X edge-processing systems with our Prime partner’s platforms and mission systems, we believe we can deliver differentiated, scalable solutions for use in some of the most demanding operational environments.”

Safe Pro’s SPOTD AI platform analyzes imagery and video from virtually any drone to automatically detect and classify explosive threats and other objects of interest. The platform converts raw video into high resolution 2D and 3D geospatial models that can be rapidly shared across users and systems to support operational decision making in defense, security, and humanitarian missions. SPOTD is capable of identifying more than 150 types of landmines and unexploded ordnance (UXO), enabling scalable situational awareness across large, high-risk areas and supporting both battlefield and demining operations.

Safe Pro’s edge-based NODE systems, built on its SPOTD technology and designed for deployment in communication constrained or denied environments, have been demonstrated with the U.S. Army as part of the Transforming in Contact 2.0 initiative and other exercises. The Company believes the new teaming agreement will expand the potential use of its AI capabilities across additional U.S. Army initiatives focused on autonomy, rapid breach, and next-generation force protection.

For more information about Safe Pro’s real-world landmine and UXO detections, visit: https://safeproai.com/landmine-detections/. Information about Safe Pro Group, its subsidiaries, and technologies, can be found at https://safeprogroup.com and you connect with us on LinkedIn, Facebook, and X.

About Safe Pro Group Inc.

Safe Pro Group Inc. (NASDAQ: SPAI) is a mission-driven technology company delivering AI-enabled security and defense solutions. Through cutting-edge platforms like SPOTD, Safe Pro provides advanced situational awareness tools for defense, humanitarian, and homeland security applications globally. It is a leading provider of artificial intelligence (AI) solutions specializing in drone imagery processing, leveraging commercially available “off-the-shelf” drones with its proprietary machine learning and computer vision technology to enable rapid identification of explosives threats, providing a much safer and more efficient alternative to traditional human-based analysis methods. Built on a cloud-based ecosystem and powered by Amazon Web Services (AWS), Safe Pro Group’s scalable platform is targeting multiple markets that include commercial, government, law enforcement and humanitarian sectors where its Safe Pro AI software, Safe-Pro USA protective gear and Airborne Response drone-based services can work in synergy to deliver safety and operational efficiency. For more information on Safe Pro Group Inc., please visit https://safeprogroup.com/.

Forward-Looking Statements

Some of the statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements relate to future events, future expectations, plans and prospects. Forward-looking statements in this press release include, without limitation, Safe Pro’s ability to support U.S. Army operations, its ability to integrate its technology with autonomous vehicles and third-party systems and the acceptance of its solutions by potential government, military and humanitarian organizations. Although Safe Pro Group believes the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Safe Pro Group has attempted to identify forward-looking statements by terminology including ”believes,” ”estimates,” ”anticipates,” ”expects,” ”plans,” ”projects,” ”intends,” ”potential,” ”may,” ”could,” ”might,” ”will,” ”should,” ”approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including market and other conditions. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth under Item 1A. in the Company’s most recently filed Form 10-K and updated from time to time in the Company’s Form 10-Q filings and in other filings with the Securities and Exchange Commission (the “SEC”), copies of which may be obtained from the SEC’s website at www.sec.gov. Any forward-looking statements contained in this press release speak only as of its date. Safe Pro Group undertakes no obligation to update any forward-looking statements contained in this press release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events, except as required by law.

Media Relations for Safe Pro Group Inc.:

[email protected]

Investor Contact:

Ankit Hira, Managing Director
Solebury Strategic Communications for Safe Pro Group Inc.
[email protected]

ROCKAWAY, N.J., April 29, 2026 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will report financial results for the first quarter ended March 31, 2026, after the close of the market on Wednesday, May 6, 2026.

Management will host a webinar at 4:30 PM EDT to review the financial results and answer questions. Investors can access the webinar using the details below:

Wednesday, May 6, 4:30 PM EDT


Dial-In: (646) 931-3860
Webinar ID: 856 5438 2775
Passcode: 895430
Registration Link: Click here to participate and ask questions on the call.

About electroCore, Inc.

electroCore, Inc. is a bioelectronic technology company whose mission is to improve health and quality of life through innovative non-invasive bioelectronic technologies. The Company’s two leading prescription products, gammaCore® non-invasive vagus nerve stimulation (nVNS) and Quell® neurostimulator, treat chronic pain syndromes through non-invasive neuromodulation technology. Additionally, the company commercializes its handheld, and personal use Truvaga™ and TAC-STIM™ nVNS products utilizing bioelectronic technologies to promote general wellness and human performance.

For more information, visit www.electrocore.com.

Contact:

ECOR Investor Relations
(973) 302-9253
[email protected]

PRINCETON, N.J., April 29, 2026 (GLOBE NEWSWIRE) — UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report first quarter 2026 financial results on Wednesday, May 6^th, 2026, prior to the open of the stock market. The announcement will be followed by a live audio webcast and conference call at 10:00 AM Eastern Time.

A live public webcast of the earnings conference call can be accessed on UroGen’s Investor Relations website. Following the live webcast, a replay will be available on the site for approximately 30 days.

About UroGen Pharma Ltd.

UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel^® reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit www.UroGen.com to learn more or follow us on X, @UroGenPharma.

INVESTOR CONTACT:

Vincent Perrone
Senior Director, Investor Relations
[email protected]
609-460-3588 ext. 1093

MEDIA CONTACT:

Cindy Romano
Director, Corporate Communications
[email protected]
609-460-3566 ext. 1083

Celebration, FL, April 29, 2026 (GLOBE NEWSWIRE) — La Rosa Holdings Corp. (NASDAQ: LRHC) (“La Rosa” or the “Company”), a real estate and PropTech enterprise, today announced that it has been appointed the exclusive listing agent in the United States for Flor de Pacífico, a visionary new residential development located in the heart of Guanacaste, Costa Rica.

Flor de Pacífico is a master-planned community designed to redefine modern living by seamlessly blending architecture with the natural environment. Located in Guanacaste, one of Costa Rica’s most sought-after regions, Flor de Pacífico offers residents proximity to pristine beaches, world-class surfing, eco-tourism attractions, and a growing infrastructure that continues to attract international investors and second-home buyers. The initial offering within the development includes the Luz del Mar Residences, a collection of thoughtfully designed homes that reflect the project’s commitment to elegance, comfort, and environmental integration.

Under the terms of the agreement, La Rosa will lead all U.S.-based sales and marketing efforts for the project over an initial five-year term. The Company will earn a 10% commission on transactions facilitated through its intermediation during this period. Phase 1 of Flor de Pacífico is expected to generate approximately $20 million in total sales, with additional phases planned that are anticipated to significantly increase the overall value of the project.

“This partnership represents an exciting milestone for La Rosa as we expand our international footprint and bring distinctive global opportunities to U.S. buyers,” said Joe La Rosa, CEO of the Company. “Phase 1 alone represents an approximately $20 million sales pipeline, and we see strong demand from U.S. buyers seeking premium international real estate. Importantly, this is just the beginning, Flor de Pacífico is a multi-phase development with the potential to scale into a significantly larger, multi-million-dollar project. Based on the success of Phase 1, we expect to have the opportunity to participate in future phases, which could meaningfully expand our revenue potential and deepen our presence in the Costa Rica market.”

About
La Rosa Holdings Corp.

La Rosa Holdings Corp. (Nasdaq: LRHC) intends to transform the real estate industry by providing agents with flexible compensation options, including a revenue-sharing model or a fee-based structure with 100% commission. Powered by its proprietary technology platform, La Rosa aims to equip agents and franchisees with the tools they need to deliver exceptional service.

The Company offers both residential and commercial real estate brokerage services, as well as technology-driven products and support for its agents and franchise partners. Its business model includes internal services for agents and external offerings for the public, spanning real estate brokerage, franchising, education and coaching, and property management.

La Rosa operates 24 corporate-owned brokerage offices across Florida, California, Texas, Georgia, and Puerto Rico. La Rosa also started its expansion into Europe, beginning with Spain. Additionally, the Company has five franchised offices and branches and three affiliated brokerage locations in the U.S. and Puerto Rico. The Company also operates a full-service escrow settlement and title company in Florida.

For more information, please visit: https://www.larosaholdings.com.

Stay connected with La Rosa, sign up for news alerts here: larosaholdings.com/email-alerts.

Forward-Looking Statements

This press release contains forward-looking statements regarding the Company’s current expectations that are subject to various risks and uncertainties. Such statements include statements regarding the Company’s ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words.  These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including without limitation, the Company’s ability to achieve profitable operations, customer acceptance of new services, the demand for the Company’s services and the Company’s customers’ economic condition, the impact of competitive services and pricing, general economic conditions, the successful integration of the Company’s past and future acquired brokerages, the effect of the recent National Association of Realtors’ landmark settlement on our business operations, and other risk factors detailed in the Company’s filings with the United States Securities and Exchange Commission (the “SEC”). You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and other reports and documents that we file from time to time with the SEC. Forward-looking statements contained in this press release are made only as of the date of this press release, and La Rosa does not undertake any responsibility to update any forward-looking statements in this release, except as may be required by applicable law. References and links to websites have been provided as a convenience, and the information contained on such websites has not been incorporated by reference into this press release.

For more information, contact: [email protected]

Investor Relations Contact:

Crescendo Communications, LLC
David Waldman/Natalya Rudman
Tel: (212) 671-1020
Email: [email protected]

ATLANTA, April 29, 2026 (GLOBE NEWSWIRE) — DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading provider of science research and development, systems engineering and integration, and digital transformation and cyber security solutions to federal agencies, will release financial results for the fiscal second quarter ended March 31, 2026 on May 6, 2026 after the market closes. DLH will then host a conference call for the investment community at 10:00 a.m. Eastern Time the following day, May 7, 2026, during which members of senior management will make a brief presentation focused on the financial results and operating trends. A question-and-answer session will follow.

Interested parties may listen to the conference call by dialing 888-347-5290 or 412-317-5256. Presentation materials will also be posted on the Investor Relations section of the DLH website prior to the commencement of the conference call. A digital recording of the conference call will be available for replay two hours after the completion of the call and can be accessed on the DLH Investor Relations website or by dialing 1-855-669-9658 and entering the conference ID 6965160.

About DLH


DLH (NASDAQ: DLHC) enhances technology, public health, and cyber security readiness missions through science, technology, cyber, and engineering solutions and services. Our experts solve some of the most complex and critical missions faced by federal customers, leveraging digital transformation, artificial intelligence, advanced analytics, cloud-based applications, telehealth systems, and more. With a world-class workforce dedicated to the idea that “Your Mission is Our Passion,” DLH brings a unique combination of government sector experience, proven methodology, and unwavering commitment to innovative solutions to improve the lives of millions. For more information, visit www.DLHcorp.com.

INVESTOR RELATIONS

Contact: Chris Witty
Phone: 646-438-9385
Email: [email protected]

– Discussions to highlight total artificial heart therapy, advanced heart failure market, and next-generation platform development –

TUCSON, Ariz., April 29, 2026 (GLOBE NEWSWIRE) — Picard Medical, Inc. (NYSE American: PMI) (“Picard Medical” or the “Company”), parent company of SynCardia Systems LLC (“SynCardia”), maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, announced today it has been featured in a two-part interview series with Joe Mullings, Chairman and Chief Executive Officer of The Mullings Group Companies, a premier global executive search firm specialized in the MedTech, HealthTech, and Life Sciences industries. Filmed, edited, and produced by Dragonfly, A TMG Company, the series features an in-depth discussion with Picard Medical Chief Executive Officer, Patrick N.J. Schnegelsberg, focused on advanced heart failure and the role of total artificial heart technology in patients with end-stage biventricular failure.

The discussions outline the clinical use of the SynCardia Total Artificial Heart, the only U.S. FDA-approved total artificial heart, which replaces the pumping function of the native heart, and is used as a bridge to transplant for patients awaiting donor organs. Mr. Schnegelsberg also highlights the Company’s innovation strategy, including development of its next generation fully implantable platform, the Emperor Total Artificial Heart, designed to improve patient mobility and expand access to therapy.

“For patients with end-stage biventricular failure, total artificial heart therapy is often the only viable option,” Mr. Schnegelsberg emphasized during the first interview. “We are delivering that solution today, while advancing a fully implantable platform designed to expand access and redefine long term mechanical heart replacement.”

The interviews also examine broader dynamics in the heart failure treatment landscape, including the limitations of existing therapies, the gap between patient demand and available treatment options, and ongoing innovation in the space.

The full interview series is available for replay at these links:

https://www.youtube.com/watch?v=S2TdsPB5wuU

https://www.youtube.com/watch?v=ziLhhWEamN0

About The Mullings Group Companies

Founded in 1992, The Mullings Group is an executive search, media/marketing, and advisory firm focused on medtech, healthtech, and life sciences. The firm has completed more than 9,000 placements across over 900 companies globally. The firm provides executive search services across all levels, from individual contributors to C-suite and board roles, and supports hiring initiatives ranging from targeted placements to large scale team builds. Its advisory services include organizational design, succession planning, and strategic initiatives aligned with client objectives. Through Dragonfly, its media and marketing company, The Mullings Group develops employer branding, thought leadership, and positioning strategies aimed at attracting talent and capital. Headquartered in Delray Beach, Florida, the firm operates offices across the United States, Canada, the United Kingdom, Israel, and Asia Pacific.

About Picard Medical and SynCardia

Picard Medical, Inc. is the parent company of SynCardia Systems, LLC (“SynCardia”), the Tucson, Arizona–based leader with the only commercially available total artificial heart technology for patients with end-stage heart failure. SynCardia develops, manufactures, and commercializes the SynCardia Total Artificial Heart (“STAH”), an implantable system that assumes the full functions of a failing or failed human heart. It is the first artificial heart approved by both the FDA and Health Canada, and it remains the only commercially available artificial heart in the United States and Canada. With more than 2,100 implants performed at hospitals across 27 countries, the STAH is the most widely used and extensively studied artificial heart in the world. For additional information about Picard Medical, please visit www.picardmedical.com or review the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”) at www.sec.gov.

Forward-Looking Statements

This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. These statements include, but are not limited to, statements regarding the development and design of the Emperor Total Artificial Heart. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. Additional information about the Company, including risk factors that may affect the Company’s business, financial condition, and results of operations, is contained in the Company’s filings with the SEC, including the Company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, which are available free of charge on the SEC’s website at http://www.sec.gov and on the Company’s investor relations website at https://picardmedical.com/.

Contact:

Investors
Eric Ribner
Managing Director
LifeSci Advisors LLC
[email protected]

Picard Medical, Inc./SynCardia Systems, LLC
[email protected]

General/Media
Brittany Lanza
[email protected]

SINGAPORE, April 29, 2026 (GLOBE NEWSWIRE) — GCL Global Holdings Ltd (Nasdaq: GCL) (GCL” or the “Company”), a leading provider of games and entertainment, today announced that its publishing subsidiary, 4Divinity Pte. Ltd. (“4Divinity”), has entered into a Memorandum of Understanding (the “MOU”) with Chengdu Cangmo Information Technology Co., Ltd. (“Chengdu Cangmo”), the developer of the upcoming action-stealth role-playing game (“RPG”) “A Whisper of Fall: Jinyiwei.” The MOU sets forth the principal terms of a proposed worldwide publishing arrangement and contemplates the execution of a definitive publishing agreement between the parties. Subject to the execution of such definitive agreement and satisfaction of customary conditions, 4Divinity is expected to serve as the worldwide publisher for the title across PC, console, and mobile platforms.

The partnership will bring together 4Divinity’s global publishing, marketing, and distribution infrastructure with Chengdu Cangmo’s development expertise in cinematic, narrative-driven action experiences. The parties intend to jointly steward the title’s launch campaign, localization, and long-term live operations across international markets, subject to definitive agreement between the parties.

About “A Whisper of Fall: Jinyiwei”

The game is a single-player action-stealth RPG set in the Ming Dynasty era, with Jinyiwei, also known as the Embroidered Uniform Guard, referring to the imperial secret police, intelligence agency, and elite bodyguards loyal to the dynasty. Players will step into the role of a Jinyiwei, caught in a web of court conspiracies and betrayal. The game combines visceral martial-arts combat, stealth infiltration, and rooftop traversal with sandbox-style levels that reward investigation and deduction.

“A Whisper of Fall: Jinyiwei” is Chengdu Cangmo’s debut title which has been in active development since 2022. It was selected as a PlayStation China Hero Project, a Sony Interactive Entertainment’s initiative for Chinese developers.

“Chengdu Cangmo has emerged as one of the most compelling new voices in Chinese AA game development, and ‘A Whisper of Fall: Jinyiwei’ exemplifies the kind of ambitious, culturally distinctive IP we aim to elevate on a global stage,” said Sebastian Toke, Group CEO of GCL. “4Divinity’s investment reflects our strategic commitment to identifying and scaling high-potential studios, and we are proud to support a team with both creative talent and long-term franchise value.”

“We have dedicated several years to developing a game that captures the depth, atmosphere, and moral complexity of the late Ming era,” said Liu Qiwei, founder of Chengdu Cangmo. “With 4Divinity’s support, we can remain focused on delivering a deeply immersive and authentic experience, while benefiting from the operational expertise and global infrastructure needed to bring to life the artistic vision that has guided this project from its inception.”

“A Whisper of Fall: Jinyiwei” is currently scheduled to launch on PlayStation 5 and PC in 2027.

About GCL Global Holdings

GCL Global Holdings Ltd. (“GCL”) is a holding company incorporated in the Cayman Islands (GCL together with its subsidiaries, the “GCL Group”). Through its operating subsidiaries, GCL Group unites people through its ecosystem of content and hardware in games and entertainment, enabling creators to deliver engaging experiences to gaming communities worldwide with a strategic focus on the rapidly expanding Asian gaming market.

Drawing on a deep understanding of gaming trends and market dynamics, GCL Group leverages its diverse portfolio of digital and physical content as well as multimedia peripherals to bridge cultures and reach a global audience by introducing Asian-developed IP across consoles, PCs, and streaming platforms. Learn more at https://www.gclglobalholdings.com/

About 4Divinity

4Divinity is a digital and retail games publishing company and an indirect majority-owned subsidiary of GCL, focused on bringing exciting game content from around the world to Asia and introducing Asian content to a global market. Along with its sister company, Epicsoft Asia, 4Divinity is partnering with publishers and development studios to introduce brand-new IP to the region.

https://www.4divinity.com/

About Chengdu Cangmo Information Technology Co., Ltd.

Founded in Chengdu, China, Chengdu Cangmo is an independent game development studio specializing in narrative-driven, cinematic action experiences rooted in Chinese history and culture. The studio’s debut title, “A Whisper of Fall: Jinyiwei,” is supported by the PlayStation China Hero Project and is being developed for PlayStation 5 and PC.

Forward-Looking Statements

This press release includes “forward-looking statements” made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995, and may be identified by the use of words such as “estimate,” “plan,” “project,” “forecast,” “intend,” “will,” “expect,” “anticipate,” “believe,” “seek,” “target” or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements may also include, but are not limited to, statements regarding projections, estimates and forecasts of revenue and other financial and performance metrics, projections of market opportunity and expectations, the estimated implied enterprise value of GCL, GCL’s ability to scale and grow its business, the advantages and expected growth of GCL, and GCL’s ability to source and retain creative talent and publish games. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of GCL’s management and are not predictions of actual performance.

These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from those expressed or implied by these forward-looking statements. Although GCL believes that it has a reasonable basis for each forward-looking statement contained in this press release, GCL cautions you that these statements are based on a combination of facts and factors currently known and projections of the future, which are inherently uncertain. In addition, there are risks and uncertainties described in GCL’s annual report on Form 20-F for the fiscal year ended March 31, 2025, as amended, and other documents filed by GCL from time to time with the SEC. These filings may identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. GCL cannot assure you that the forward-looking statements in this press release will prove to be accurate. There may be additional risks that GCL presently knows or that GCL currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In light of the significant uncertainties in these forward-looking statements, nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. The forward-looking statements in this press release represent the views of GCL as of the date of this press release. Subsequent events and developments may cause those views to change. However, while GCL may update these forward-looking statements in the future, there is no current intention to do so, except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing the views of GCL as of any date subsequent to the date of this press release. Except as may be required by law, GCL does not undertake any duty to update these forward-looking statements.

GCL Investor Relations:

Crocker Coulson
[email protected]
(646) 652-7185

Supports development and standardization of manufacturing processes for scalable reactor deployment

Advances the transition from design to industrial execution and repeatable production, from FOAK to NOAK

Builds on existing supply chain collaboration to support secure, end-to-end execution and transition toward direct procurement and purchase order implementation

NEW YORK, April 29, 2026 (GLOBE NEWSWIRE) — Terra Innovatum Global N.V. (NASDAQ: NKLR) (“Terra” or the “Company”), developer of the SOLO™ Micro-Modular Reactor, today announced that it has entered into a collaboration agreement with Conuar, a leading manufacturer of nuclear fuel and zirconium alloy components, to advance fabrication methods and manufacturing readiness, a critical step in enabling repeatable, fleet-scale deployment of the SOLO™ platform.

The agreement focuses on the development and standardization of manufacturing processes for structural and functional components in zirconium alloys and stainless steel – materials that are fundamental to reactor core performance and require specialized, nuclear-grade fabrication capabilities.

By leveraging Conuar’s expertise in zirconium alloy fabrication, Terra Innovatum will advance constructability studies and define industrially viable production methods, bridging reactor design to real-world manufacturing execution. Zirconium alloy fabrication represents a highly specialized and capacity-constrained segment of the nuclear supply chain. Establishing qualified, repeatable manufacturing processes for these components is a critical step toward enabling fleet-scale deployment of advanced reactor systems.

“Partnering with Conuar gives Terra Innovatum access to specialized expertise in zirconium alloy fabrication, a critical capability for advanced reactor systems,” said Alessandro Petruzzi, Co-Founder and Chief Executive Officer of Terra Innovatum. “This collaboration will help accelerate the development of standardized manufacturing processes that support both FOAK deployment and scalable NOAK production. It is an important step in strengthening the manufacturability, repeatability, and scalability of the SOLO™ reactor.”

For Conuar, this agreement with Terra Innovatum is more than a partnership. It represents a step toward building a more resilient and scalable nuclear supply chain. For over 40 years, CONUAR has operated in some of the world’s most demanding industrial environments. That experience has expanded its capabilities beyond nuclear fuel fabrication into the engineering and industrialization of critical reactor components.

“At Conuar, we focus on the fabrication of nuclear fuel and the industrialization of advanced materials such as zirconium alloys, titanium, and specialty steels. Their value depends on the ability to produce them reliably, at scale, and under nuclear-grade standards. That’s where we differentiate,” said Marcelo Bercellini, Director of Sales and Business Development.

“The nuclear sector is entering a new phase of growth in which supply chain capacity is becoming the defining constraint. This agreement reflects a shared long-term commitment to strengthening that capacity and supporting the development and deployment of SOLO Micro reactors,” said Rodolfo Kramer, CEO of CONUAR.

He added, “Disciplined execution, strong industrial capabilities, and aligned partnerships are essential to accelerating the deployment of safer, more efficient, and scalable nuclear solutions worldwide. This is the direction Terra Innovatum is driving forward.”

Establishing standardized manufacturing processes for core components is a critical step toward repeatable, fleet-scale deployment of the SOLO™ platform, aligning engineering, supply chain, and fabrication processes to address critical constraints to scalable execution.

ABOUT CONUAR

Conuar is a leading nuclear development and high-precision technology manufacturer that has been serving the nuclear industry for over 40 years. The Company specializes in fuel supply and component manufacturing and has produced 100% of the nuclear fuel used by Argentina. Conuar engineers and integrates critical components with specialized engineering, advanced manufacturing, and strict adherence to international standards in demanding environments, and produces seamless tubes of high alloys for nuclear industry.

Under the agreement, Terra Innovatum and Conuar will conduct pilot programs to evaluate the scope and pricing for Conuar to supply coolant tubs and plates, control rod mechanisms, fuel rods, and stainless steel and special alloy components.

ABOUT TERRA INNOVATUM & SOLO™

Terra Innovatum’s mission is to make nuclear power accessible. We deliver simple and safe micro-reactor solutions that are scalable, affordable and deployable anywhere 1 MWe at a time.

Terra Innovatum is a pioneering force in the energy sector, dedicated to delivering innovative and sustainable power solutions. Terra Innovatum plans to leverage cutting-edge nuclear technology through the SOLO™ Micro-Modular Reactor (SMR™) to provide efficient, safe, and environmentally conscious energy. With a mission to address global energy shortages, Terra Innovatum combines extensive expertise in nuclear industry design, manufacturing, and installation licensing to offer disruptive energy solutions. Committed to propelling technological advancements, Terra Innovatum and SOLO™ are dedicated to fostering prosperity and sustainability for humankind.

It is anticipated that SOLO™ will be available globally within the next three years. Conceptualized in 2018 and engineered over six years by experts in nuclear safety, licensing, innovation, and R&D, SOLO™ addresses pressing global energy demands with a market-ready solution. Built from readily available commercial off-the-shelf components, the proven licensing path for SOLO™ enables rapid deployment and minimizes supply chain risks, ensuring final cost predictability. Designed to adapt with evolving fuel options, SOLO™ supports both LEU+ and HALEU, offering a platform ready to transition to future fuel supplies.

SOLO™ will offer a wide range of versatile applications, providing CO2-free, behind-the-meter, and off-grid power solutions for data centers, mini-grids serving remote towns and villages, and large-scale industrial operations in hard-to-abate sectors like cement production, oil and gas, steel manufacturing, and mining. It also has the ability to supply heat for industrial applications and other specialized processes, including water treatment, desalination and co-generation. Thanks to its modular design, SOLO™ can easily scale to deliver up to 1GW or more of CO2-free power with a minimal footprint, making it an ideal solution for rapidly replacing fossil fuel-based thermal plants. Beyond electricity and heat generation, SOLO™ can also contribute to critical applications in the medical sector by producing radioisotopes essential for oncology research and cancer treatment.

To learn more, visit: https://investors.terrainnovatum.com/. Follow us on X: https://x.com/TerraInnovatum and LinkedIn: https://www.linkedin.com/company/terra-innovatum-solo/.

FORWARD LOOKING STATEMENTS

This press release includes “forward-looking statements” within the meaning of the federal securities laws, including, but not limited to, opinions and projections prepared by Terra Innovatum’s management. Forward-looking statements generally relate to future events or future financial or operating performance, including pro forma and estimated financial information, and other “forward-looking statements” (as such term is defined in the Private Securities Litigation Reform Act of 1995). The recipient can identify forward-looking statements because they typically contain words such as “outlook,” “believes,” “expects,” “ will,” “projected,” “continue,” “increase,” “may,” “should,” “could,” “seeks,” “predicts,” “intends,” “trends,” “plans,” “estimates,” “anticipates” or the negatives or variations of these words or other comparable words and/or similar expressions (but the absence of these words and/or similar expressions does not mean that a statement is not forward-looking). These forward-looking statements specifically include, but are not limited to, statements regarding estimates and forecasts of financial and performance metrics, projections of market opportunity and market share, expected timing for regulatory approvals and commercialization and the potential success of Terra Innovatum’s strategy and expectations. Forward-looking statements, opinions and projections are neither historical facts nor assurances of future performance. Instead, they are based only on current beliefs, expectations and assumptions regarding the future of Terra Innovatum’s business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of Terra Innovatum’s control. These uncertainties and risks may be known or unknown. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: changes in domestic and foreign business, market, financial, political and legal conditions; failure to realize the anticipated benefits of the proposed business combination; risks relating to the uncertainty of the projected financial information with respect to Terra Innovatum; future global, regional or local economic and market conditions; the development, effects and enforcement of laws and regulations; Terra Innovatum’s ability to manage future growth; Terra Innovatum’s ability to develop new products and services, bring them to market in a timely manner, and make enhancements to its platform; the effects of competition on Terra Innovatum’s future business; and the outcome of any potential litigation, government and regulatory proceedings, investigations and inquiries and other risks and uncertainties described under the heading “Risk Factors” in documents Terra Innovatum files from time to time with the Securities and Exchange Commission. If any of these risks materialize or the Terra Innovatum’s assumptions prove incorrect, actual results could differ materially from the results implied by the forward-looking statements contained herein. In addition, forward-looking statements reflect Terra Innovatum’s expectations and views as of the date of this presentation. Terra Innovatum anticipates that subsequent events and developments will cause its assessments to change. However, while Terra Innovatum may elect to update these forward-looking statements in the future, each of them specifically disclaims any obligation to do so. Accordingly, you should not place undue reliance on the forward-looking statements, which speak only as of the date they are made.

CONTACTS

Giordano Morichi

Founding Partner, Chief Business Development Officer & Investor Relations
Terra Innovatum Global N.V.

E: [email protected]
W: www.terrainnovatum.com

Investor Relations

Simon Willcocks

Alliance Advisors IR
E: [email protected]

Media Relations

Fatema Bhabrawala

Alliance Advisors IR
E: [email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/7c6e7895-cf00-421a-9cd5-aa873cca0973